Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly ...
Jan 22, 2021
0
4
Autoinflammatory syndromes are often the result of genetic mutations that ultimately compromise neutrophils, macrophages and other cells of the innate immune system. Rather than showering sufferers with broad immunosuppressives, ...
When antibody-producing immune cells encounter infectious pathogens for the first time, they engage a signal cascade to generate a massive activation signal within seconds. The mechanisms underlying this acute initial activation ...
Nov 5, 2020
0
46
Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related ...
Oct 16, 2020
0
45
Like packaging designed to create a protective environment around a product, the mix of cells and fluids immediately surrounding human bone marrow provides critical protective and nourishing conditions for hematopoietic—or ...
Oct 6, 2020
0
64
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.
Sep 21, 2020
0
28
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance ...
Sep 14, 2020
0
7
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with ...
Aug 26, 2020
0
36
A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery. In preclinical ...
Aug 24, 2020
0
3
